Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/05 23:26:33」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes.
  • Imamura A, Kusunoki M, Ueda S, Hayashi N, Imai Y.SourceMoriya Keiyu Hospital, 980-1, Tatuzawa, Moriya City, Ibaraki, 302-0118, Japan, imamura.akira@keiyu.or.jp.
  • Diabetes therapy : research, treatment and education of diabetes and related disorders.Diabetes Ther.2013 Jan 10. [Epub ahead of print]
  • INTRODUCTION: Dapagliflozin is an orally administered selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin lowers blood glucose through a reduction in renal glucose reabsorption. This study was performed to a
  • PMID 23307267
  • Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
  • Araki E, Kawamori R, Inagaki N, Watada H, Hayashi N, Horie Y, Sarashina A, Thiemann S, von Eynatten M, Dugi K, Woerle HJ.SourceDepartment of Metabolic Medicine, Kumamoto University Graduate School of Medicine, Kumamoto, Japan.
  • Diabetes, obesity & metabolism.Diabetes Obes Metab.2012 Nov 19. doi: 10.1111/dom.12039. [Epub ahead of print]
  • AIMS: In a phase III study conducted among Japanese patients with type 2 diabetes mellitus (T2DM), linagliptin 5 and 10 mg showed clinically meaningful improvements in glycaemic parameters after 12 and 26 weeks compared with placebo and voglibose, respectively. This extension study assessed long
  • PMID 23163910

Japanese Journal

  • 糖尿病血液透析患者におけるアログリプチンの有効性と安全性の検討
  • 藤井 由季,阿部 雅紀,樋口 輝美,鈴木 紘子,松本 史郎,水野 真理,菊池 史,岡田 一義,相馬 正義
  • 日本透析医学会雑誌 46(7), 633-640, 2013
  • 糖尿病血液透析患者におけるDPP-4阻害薬アログリプチンの有効性と安全性について検討した.HbA1c(NGSP)値>6.9%またはグリコアルブミン(GA)値>20.0%で,食事・運動療法またはDPP-4阻害薬以外の経口血糖降下薬にて治療中の2型糖尿病血液透析患者28例(男性22例,女性6例,平均年齢69.9±9.5歳,平均透析歴55.0±51.0か月)を対象とした.インスリン治療中の患者は除外した …
  • NAID 130003372793
  • 低分子生体成分ミミック体の創出を基盤とする創薬化学研究
  • 高畑 廣紀
  • YAKUGAKU ZASSHI 133(5), 575-585, 2013
  • … Some of the prepared L-forms showed potent inhibitory activities towards intestinal maltase, with IC50 values comparable to those of commercial drugs such as acarbose, voglibose, and miglitol, which are used in the treatment of type 2 diabetes. …
  • NAID 130003361951
  • Effects of Voglibose and Nateglinide on Glycemic Status and Coronary Atherosclerosis in Early-Stage Diabetic Patients
  • KATAOKA Yu,YASUDA Satoshi,MIYAMOTO Yoshihiro,SASE Kazuhiro,KOSUGE Masami,KIMURA Kazuo,YOSHIMASA Yasunao,MIYAZAKI Shunichi
  • Circulation journal : official journal of the Japanese Circulation Society 76(3), 712-720, 2012-02-25
  • … The 302 patients with coronary artery disease (CAD), impaired glucose tolerance/diabetes mellitus (DM) pattern according to 75-g oral glucose tolerance test and HbA1c <6.9% were randomly assigned to life-style intervention (n=101), voglibose (0.9mg/day, n=100) or nateglinide treatment (180mg/day, n=101). … Although voglibose significantly increased the number of patients with normal glucose tolerance at 1 year, there were no significant differences in coronary atherosclerotic changes at 1 year. …
  • NAID 10030130334

Related Links

※この商品に関係するニュース記事へのリンクがページ最下部にあります。 「有効成分」 ボグリボース(Voglibose) 「同一成分含有商品」 プランディアル (ボグリボース) 0.2mg (10錠) 260 円 Prandial (Voglibose) - 0.2mg (10 Tablets) ...
- 1 - 患者向医薬品ガイド 2010年1月更新 ボグリボース錠0.2「OME」 ボグリボース錠0.3「OME」 【この薬は?】 販売名 ボグリボース錠0.2「OME」 VOGLIBOSE TABLETS 0.2「OME」 ボグリボース錠0.3「OME」 VOGLIBOSE ...

Related Pictures

Volix - voglix (Voglibose)Voglibose Voglibose .Voglibose for prevention of type 2 Prandial (Voglibose) - 4NRX (UK)VogliboseAlpha-glucosidase InhibitionDescription Voglibose.svg




α-glucodidase inhibitor, αGI
  • 食前に服用することで、食後高血糖を改善。
  • 特に高血糖の程度が高いII型糖尿病患者のhomoglobin A1c levelを改善する (GOO.1640)





  • αGI


  • ベイスン錠0.2/ベイスン錠0.3